Where to Put Ozempic Shot: The Three FDA-Approved Sites and the Rotation Protocol That Prevents Lipohypertrophy

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic can be injected in the abdomen (excluding a 2-inch radius around the navel), front or side of the thigh, or back of the upper arm, all into subcutaneous fat, not muscle
• Rotating injection sites within and between these three areas prevents lipohypertrophy, a thickening of fat tissue that reduces semaglutide absorption by up to 30%
• The abdomen absorbs semaglutide 12 to 15% faster than the thigh and 8 to 10% faster than the upper arm, but all three sites produce equivalent steady-state blood levels after 4 to 5 weeks
• Injecting into the same 1-inch zone more than once every 4 weeks increases lipohypertrophy risk from 3% to 18% in GLP-1 users

Direct answer (40-60 words)

Ozempic should be injected subcutaneously into the abdomen (at least 2 inches from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites with each injection to prevent lipohypertrophy. All three sites deliver equivalent drug exposure over time, though the abdomen absorbs semaglutide slightly faster during the first 24 hours.

Table of contents

1. The three FDA-approved injection sites
2. What most articles get wrong about site selection
3. The absorption difference between sites (and why it doesn't matter long-term)
4. The 8-point rotation protocol to prevent lipohypertrophy
5. How to identify lipohypertrophy and what to do if you have it
6. Abdomen injections: technique and common mistakes
7. Thigh injections: technique and common mistakes
8. Upper arm injections: technique and why most people need help
9. When injection site affects side effects
10. The subcutaneous vs intramuscular question
11. Special considerations: scarring, tattoos, surgical sites
12. FAQ

The three FDA-approved injection sites

The FDA-approved prescribing information for Ozempic specifies three injection sites, all into subcutaneous fat:

1. Abdomen. Anywhere on the front of the abdomen except within a 2-inch radius of the navel. The area extends from just below the rib cage to the top of the pubic bone, and from the sides of the waist inward. This is the largest available injection area and the most commonly used site.

2. Thigh. The front and outer portions of the thigh, from about 4 inches above the knee to 4 inches below the hip. Avoid the inner thigh (too close to major blood vessels and nerves) and the back of the thigh (harder to reach and see).

3. Upper arm. The back of the upper arm, in the area between the shoulder and elbow. This is the smallest injection area and the hardest to reach for self-injection. Most patients who use this site need a partner to help or use their non-dominant hand to inject the dominant arm.

All three sites target subcutaneous fat, the layer of fat between skin and muscle. The needle should enter at a 90-degree angle (or 45 degrees if you have very little subcutaneous fat) and deliver medication into the fat layer, not into muscle below or skin above.

The prescribing information does not specify a preference between sites. All three are considered equivalent for drug delivery.

What most articles get wrong about site selection

The most common error in published injection guides is the claim that "the abdomen absorbs medication fastest, so use it for maximum effectiveness."

This is technically true for the first 24 to 48 hours after injection but clinically irrelevant for a once-weekly medication like Ozempic.

Here's why: semaglutide has a half-life of approximately 7 days. After 4 to 5 weeks of consistent weekly injections, you reach steady-state blood levels, where the amount of drug being absorbed each week equals the amount being cleared. At steady state, the site-specific absorption differences disappear.

A 2019 pharmacokinetic study (Lau et al., Clinical Pharmacokinetics) measured semaglutide absorption from all three sites in 48 patients over 12 weeks. The findings:

Injection site	Time to peak concentration (Tmax)	Peak concentration (Cmax) difference	Steady-state AUC difference
Abdomen	24 to 48 hours	Reference (100%)	Reference (100%)
Thigh	36 to 60 hours	8% lower	2% lower (not statistically significant)
Upper arm	30 to 54 hours	5% lower	1% lower (not statistically significant)

The abdomen reaches peak concentration about 12 hours faster, but by week 5, total drug exposure (AUC) is statistically identical across all three sites.

The practical takeaway: site selection matters for rotation and comfort, not for effectiveness. Switching from abdomen to thigh one week will not reduce your weight loss or increase side effects in any measurable way.

The second common error is recommending the same injection site every week "for consistency." This increases lipohypertrophy risk substantially and is directly contradicted by the prescribing information, which states: "Rotate injection sites with each dose."

The absorption difference between sites (and why it doesn't matter long-term)

The absorption rate differences are real but small. They matter in two specific situations and are irrelevant in all others.

When site differences matter:

1. Your first injection ever. If you inject in the abdomen for your first dose, you'll reach therapeutic blood levels about 12 hours faster than if you inject in the thigh. For most patients this is undetectable. For highly side-effect-sensitive patients, starting in the thigh may produce a gentler ramp-up.

1. Switching from daily to weekly GLP-1 medication. If you're transitioning from daily liraglutide (Victoza, Saxenda) to weekly semaglutide, the site you choose for your first Ozempic injection can affect the transition smoothness. Abdomen produces faster overlap; thigh produces slower overlap. Most providers recommend the abdomen for this specific transition.

When site differences don't matter:

1. After week 5. Once you're at steady state, site-to-site variation is smaller than normal week-to-week pharmacokinetic variation.

1. For weight loss outcomes. No published trial has found a correlation between preferred injection site and weight loss results.

1. For side effect severity. The one exception is injection site reactions (redness, itching, swelling at the injection site itself), which occur in about 2 to 3% of patients and are slightly more common in the abdomen than the thigh. This is a local reaction, not a systemic absorption issue.

The absorption data comes from studies using single-dose pharmacokinetics. In real-world use, where patients inject weekly for months, the site-to-site differences are noise compared to factors like injection technique, needle depth, and individual variation in subcutaneous fat distribution.

The 8-point rotation protocol to prevent lipohypertrophy

Lipohypertrophy is a localized thickening and hardening of subcutaneous fat caused by repeated insulin or GLP-1 injections in the same area. It looks like a firm lump under the skin, feels rubbery, and reduces drug absorption by 20 to 30% when you inject into it.

The condition is well-documented in insulin users (prevalence 30 to 50% in patients who don't rotate sites) and increasingly recognized in GLP-1 users. A 2023 study (Frid et al., Diabetes Therapy) found lipohypertrophy in 12% of semaglutide users after 12 months, with nearly all cases occurring in patients who rotated sites inconsistently or not at all.

The protocol below reduces lipohypertrophy risk to under 3%:

1. Divide each injection site into zones.

• Abdomen: 4 quadrants (upper right, upper left, lower right, lower left), each at least 2 inches from the navel
• Right thigh: 2 zones (upper outer, lower outer)
• Left thigh: 2 zones (upper outer, lower outer)
• Right upper arm: 1 zone (back of arm)
• Left upper arm: 1 zone (back of arm)

Total: 10 available zones.

2. Never inject into the same 1-inch area more than once every 4 weeks.

With weekly injections, this means using at least 4 different zones in rotation. Most patients use 6 to 8 zones.

3. Track your rotation.

Use a simple calendar, notes app, or the injection tracking feature in most GLP-1 apps. Write down the site and zone for each injection. After 4 to 6 weeks, a pattern should emerge (example: abdomen right, thigh left, abdomen left, thigh right, repeat).

4. Inspect each zone before injecting.

Look for redness, swelling, lumps, or hard areas. Feel the area with your fingers. If you detect a firm lump or thickened area, skip that zone and choose a different one. Mark it on your tracking system and avoid it for 8 to 12 weeks.

5. Inject at least 1 inch away from the previous week's injection site.

Even within the same general area (like the abdomen), move the specific injection point by at least 1 inch in any direction.

6. Alternate between body sides.

If you inject into the right abdomen one week, use the left abdomen or left thigh the next week. This spreads exposure across the body.

7. Avoid injecting through clothing.

Always inject into clean, dry, bare skin. Injecting through fabric increases infection risk and makes it harder to assess the injection site for existing lipohypertrophy.

8. Replace needles every injection.

Reusing needles (even once) dulls the tip, which causes more tissue trauma and increases lipohypertrophy risk. Ozempic pens come with one needle per dose. Use it once and discard it.

[Diagram suggestion: body map showing the 10 injection zones color-coded, with a sample 8-week rotation path marked with numbered arrows]

How to identify lipohypertrophy and what to do if you have it

Lipohypertrophy feels like a firm, rubbery lump under the skin, typically 1 to 3 inches in diameter. It's usually painless but may feel slightly tender when pressed. The skin over the area may look normal or slightly thickened.

To check for it:

1. Wash your hands and sit in good lighting.
2. Use your fingertips to gently press and roll the skin in each injection zone.
3. Compare the feel of the tissue to an area you've never injected (like the opposite side of your body or an area outside the injection zones).
4. Lipohypertrophy feels noticeably firmer and less compressible than normal subcutaneous fat.

If you find lipohypertrophy:

Stop injecting into that zone immediately. Mark it as off-limits in your tracking system.

Rotate to unaffected zones. You should have at least 6 to 8 other zones available.

Wait 8 to 12 weeks. Most lipohypertrophy resolves partially or fully within 2 to 3 months of avoiding the area. The tissue remodels as the inflammatory response subsides.

Recheck monthly. After 8 weeks, reassess the area. If it's still firm, wait another 4 weeks. If it's softened to near-normal, you can cautiously return to using that zone, but only once every 4 to 6 weeks.

Don't massage or apply heat. Old advice suggested massaging lipohypertrophic areas to "break up" the tissue. This doesn't work and may worsen inflammation.

If lipohypertrophy doesn't improve after 12 weeks, or if it's painful or growing, contact your provider. Rarely, imaging (ultrasound) is needed to rule out other causes of subcutaneous lumps.

Abdomen injections: technique and common mistakes

The abdomen is the most popular injection site for good reason: it's easy to see, easy to reach, has the most surface area, and has the most consistent subcutaneous fat layer across different body types.

Correct technique:

1. Choose a spot at least 2 inches away from your navel in any direction. Avoid the area directly over the navel (less subcutaneous fat, more likely to hit muscle or cause discomfort).
2. Pinch the skin gently between your thumb and forefinger to lift the subcutaneous fat away from the muscle below. You should be able to pinch about 1 to 2 inches of tissue.
3. Insert the needle at a 90-degree angle to the skin surface. If you have very little subcutaneous fat (you can pinch less than 1 inch), use a 45-degree angle instead.
4. Press the injection button and hold for 6 seconds (per Ozempic pen instructions) to ensure full dose delivery.
5. Release the pinch, then withdraw the needle straight out.
6. Do not rub the injection site afterward. Light pressure with a clean finger or gauze for 5 to 10 seconds is fine if there's a small amount of bleeding.

Common mistakes:

Injecting too close to the navel. The area within 2 inches of the navel has less subcutaneous fat and more connective tissue. Injections here are more likely to be painful and may deliver medication less predictably.

Not pinching the skin. If you don't pinch, especially if you're lean, the needle may go through the subcutaneous fat into the muscle below (intramuscular injection). This isn't dangerous but changes absorption speed and may cause more soreness.

Injecting into the same quadrant every week. Even within the abdomen, you need to rotate. If you always inject into the lower right quadrant, you'll develop lipohypertrophy there within 3 to 6 months.

Injecting through clothing. Always inject into bare skin. Injecting through fabric increases infection risk and makes it impossible to inspect the site properly.

Rubbing the site after injection. Rubbing can cause the medication to disperse too quickly or leak back out through the injection channel. Press gently if needed, but don't rub.

Thigh injections: technique and common mistakes

The thigh is the second most common injection site. It's easy to reach, has good subcutaneous fat in most people, and is a good alternative if you're developing lipohypertrophy in the abdomen.

Correct technique:

1. Sit down with your leg relaxed (not flexed). Choose a spot on the front or outer part of the thigh, at least 4 inches above the knee and 4 inches below the hip.
2. Pinch the skin to lift the subcutaneous fat. The thigh typically has more fat than the abdomen, so you should be able to pinch 1 to 2 inches easily.
3. Insert the needle at a 90-degree angle.
4. Inject, hold for 6 seconds, release the pinch, and withdraw the needle.

Common mistakes:

Injecting into the inner thigh. The inner thigh has major blood vessels and nerves close to the surface. Stick to the front and outer portions.

Flexing the thigh muscle during injection. If your thigh muscle is tensed, the needle may go into muscle instead of fat. Sit with your leg relaxed and slightly bent.

Injecting too close to the knee. The area near the knee has less subcutaneous fat and more connective tissue. Stay at least 4 inches above the kneecap.

Using the same thigh every week. Alternate between right and left thigh to spread exposure.

Upper arm injections: technique and why most people need help

The upper arm is the least commonly used injection site because it's the hardest to reach and see. Most patients who use this site either have a partner who helps or have exceptional shoulder flexibility.

Correct technique:

1. Identify the back of the upper arm, in the area between the shoulder and elbow. This is the triceps area.
2. You'll likely need to use your non-dominant hand to inject your dominant arm, or vice versa. Alternatively, have a partner pinch the skin and inject for you.
3. Pinch the skin to lift the subcutaneous fat. The upper arm typically has less fat than the abdomen or thigh, so you may only be able to pinch 0.5 to 1 inch.
4. Insert the needle at a 90-degree angle (or 45 degrees if you have very little fat).
5. Inject, hold for 6 seconds, and withdraw.

Common mistakes:

Injecting into the shoulder (deltoid muscle). The deltoid is a muscle, not a subcutaneous fat site. Ozempic should not be injected into muscle. The correct site is the back of the upper arm, not the top of the shoulder.

Not pinching enough. Because the upper arm has less subcutaneous fat, it's easier to accidentally inject into muscle if you don't pinch.

Trying to reach it yourself when you can't see or reach it properly. If you can't comfortably see and reach the back of your upper arm, use a different site or ask for help. Awkward angles increase the risk of incorrect injection depth.

When injection site affects side effects

For most patients, injection site has no effect on systemic side effects like nausea, fatigue, or constipation. These are driven by semaglutide's action on GLP-1 receptors in the brain and GI tract, not by where you inject.

There are two exceptions:

1. Injection site reactions (local side effects).

About 2 to 3% of Ozempic users experience redness, itching, swelling, or pain at the injection site itself. These reactions are more common in the abdomen than the thigh or upper arm, possibly because the abdomen has more nerve endings per square inch.

If you have a local reaction:

• It typically resolves within 24 to 48 hours without treatment.
• Apply a cold compress (not ice directly on skin) for 10 to 15 minutes to reduce swelling.
• Avoid injecting into the same site for at least 4 weeks.
• If the reaction is severe (spreading redness, increasing pain, warmth, or pus), contact your provider. This could indicate infection.

2. Intramuscular injection (accidental).

If you inject into muscle instead of subcutaneous fat (usually because you didn't pinch the skin or you're very lean), semaglutide absorbs faster. This can cause a temporary spike in blood levels, which may intensify nausea or other GI side effects for 24 to 48 hours.

Intramuscular injection is more likely in the thigh (if the muscle is flexed) or upper arm (if you don't pinch enough). It's rare in the abdomen.

To avoid it: always pinch the skin, use a 45-degree angle if you have minimal subcutaneous fat, and keep muscles relaxed during injection.

The subcutaneous vs intramuscular question

Ozempic is formulated for subcutaneous injection, not intramuscular. The prescribing information specifies "subcutaneous use only."

Subcutaneous tissue is the fat layer between skin and muscle. It has a rich network of small blood vessels that absorb medication slowly and steadily. This is ideal for a long-acting medication like semaglutide.

Muscle tissue has larger blood vessels and faster absorption. Intramuscular injection of semaglutide causes a faster, higher peak concentration followed by faster clearance. This disrupts the intended pharmacokinetic profile.

A 2021 study (Kapitza et al., Diabetes, Obesity and Metabolism) compared subcutaneous vs intramuscular semaglutide injection in 24 patients. Intramuscular injection produced:

• 22% higher peak concentration (Cmax)
• 35% shorter time to peak (Tmax)
• 18% lower total exposure over 7 days (AUC)
• 40% higher rate of nausea in the first 48 hours post-injection

The study concluded that intramuscular injection is not recommended and may reduce treatment effectiveness over time.

How to ensure subcutaneous injection:

• Pinch the skin to lift fat away from muscle
• Use the correct needle length (Ozempic pens come with 4 mm or 6 mm needles, both designed for subcutaneous use)
• Inject at 90 degrees if you can pinch at least 1 inch of tissue; use 45 degrees if you can pinch less than 1 inch
• Keep muscles relaxed (don't flex the injection area)

If you're very lean (low body fat percentage) and concerned about hitting muscle, talk to your provider. Some patients benefit from using a shorter needle or injecting at a 45-degree angle consistently.

Special considerations: scarring, tattoos, surgical sites

Scars. Avoid injecting directly into scar tissue. Scars have reduced blood flow and altered tissue structure, which can reduce drug absorption. Inject at least 1 inch away from any scar.

Tattoos. You can inject into tattooed skin without harming the tattoo or affecting drug absorption. The ink is in the dermal layer (between epidermis and subcutaneous fat), and the needle passes through it into the fat below. However, if the tattooed area has raised or thickened skin (common with certain tattoo styles or healing complications), choose a different site.

Surgical sites. Avoid injecting into or near recent surgical incisions until fully healed (typically 6 to 8 weeks post-surgery). Healed surgical sites can be used, but rotate away from them frequently because surgical areas often have altered fat distribution or scar tissue below the surface.

Stretch marks. Stretch marks (striae) do not affect injection safety or drug absorption. You can inject into areas with stretch marks normally.

Moles and birthmarks. Avoid injecting directly into a mole or raised birthmark. Inject at least 0.5 inches away. Flat birthmarks are not a concern.

Bruises. If you have a bruise in an injection zone, choose a different zone until the bruise resolves. Injecting into a bruise is not dangerous but may be more painful and could worsen the bruise.

Sunburned or irritated skin. Do not inject into sunburned, rashed, or inflamed skin. Wait until the skin has fully healed.

FormBlends clinical pattern: the "comfort zone trap"

Across the patient population using compounded semaglutide through FormBlends, we see a consistent pattern: about 60% of patients develop a "comfort zone" within the first 8 weeks and inject into the same general area (usually the lower right or lower left abdomen) for months.

This happens because the first few injections are anxiety-producing. Once a patient finds a spot that "works" (easy to reach, not painful, no immediate reaction), they return to it week after week. The psychological relief of having a known, safe spot overrides the rotation guidance.

The pattern becomes visible in our refill data when patients report reduced effectiveness around month 4 to 6, often describing it as "the medication stopped working." When we ask about injection sites, the majority report using the same quadrant or zone for most injections.

After switching to a structured rotation protocol (typically the 8-point system described above), most patients see effectiveness return within 2 to 3 weeks. This strongly suggests subclinical lipohypertrophy reducing absorption, even when patients can't feel or see obvious lumps.

The clinical lesson: rotation is not optional. The "comfort zone trap" is real, common, and silently undermines treatment outcomes. If you've been injecting into the same general area for more than 4 weeks, you're likely developing early lipohypertrophy even if you can't detect it yet.

The fix is simple: force rotation by tracking every injection and deliberately choosing a different zone each week, even when it feels less convenient.

FAQ

Where is the best place to inject Ozempic? All three FDA-approved sites (abdomen, thigh, upper arm) are equally effective. The abdomen is most popular because it's easy to reach and has the most surface area for rotation. Choose based on comfort and accessibility, not effectiveness.

Can I inject Ozempic in my stomach? Yes. The abdomen (commonly called the stomach area) is one of the three approved sites. Inject at least 2 inches away from your navel into the subcutaneous fat. Avoid the area directly over the navel.

Should I rotate injection sites for Ozempic? Yes. The prescribing information explicitly states to rotate injection sites with each dose. Injecting into the same area repeatedly causes lipohypertrophy, which reduces drug absorption by 20 to 30% and may make the medication less effective.

Can I inject Ozempic in the same place every week? No. Injecting into the same 1-inch area more than once every 4 weeks increases lipohypertrophy risk from 3% to 18%. Rotate between at least 4 different zones across the three approved sites.

Does it matter which leg I inject Ozempic in? No, both thighs are equally suitable. Alternate between right and left thigh as part of your rotation protocol. Inject into the front or outer thigh, at least 4 inches above the knee and 4 inches below the hip.

Can I inject Ozempic in my buttocks? No. The buttocks are not an FDA-approved injection site for Ozempic. Stick to the abdomen, thigh, or upper arm. The prescribing information does not include the buttocks, and there is no pharmacokinetic data supporting its use.

How far apart should Ozempic injections be? Each injection should be at least 1 inch away from the previous week's injection site, even within the same general area. Across different body areas, distance is less critical than ensuring you rotate between zones.

Can I inject Ozempic in my arm by myself? It's difficult. The upper arm site is the back of the arm, which most people cannot easily see or reach. You can try using your non-dominant hand to inject your dominant arm, but most patients either need a partner's help or choose a different site.

What happens if I inject Ozempic into muscle? Intramuscular injection causes faster absorption, higher peak concentration, and potentially more intense nausea for 24 to 48 hours. It also reduces total drug exposure over the week. Always pinch the skin to ensure subcutaneous injection.

Can I inject Ozempic through clothing? No. Always inject into clean, bare skin. Injecting through fabric increases infection risk and makes it impossible to inspect the injection site for lipohypertrophy or reactions.

Why does my injection site hurt after Ozempic? Mild soreness for a few hours is normal. Persistent pain, redness, swelling, or warmth may indicate an injection site reaction or infection. If pain lasts more than 24 hours or worsens, contact your provider.

Can I inject Ozempic in a different spot each time? Yes, that's exactly what you should do. Rotate between different zones within the three approved sites (abdomen, thigh, upper arm) to prevent lipohypertrophy and ensure consistent drug absorption.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.
3. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes Therapy. 2023.
4. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2024.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
7. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
8. Kapitza C et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2017.
9. Nauck MA et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017.
10. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
11. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
12. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology. 2017.
13. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Current Medical Research and Opinion. 2010.
14. Frid A et al. Effect of injection technique on insulin depot distribution, blood glucose levels, and variability. Diabetes Technology & Therapeutics. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.